Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2026 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
January 05, 2026 08:05 ET | Source: ABLi Therapeutics

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a Disease-modifying Therapy for Parkinson’s Disease

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW...
January 05, 2026 08:05 ET | Source: LifeMD, Inc.

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk’s Wegovy®...
January 05, 2026 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)

CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical...
January 05, 2026 08:00 ET | Source: Humacyte, Inc

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle...
January 05, 2026 08:00 ET | Source: UroGen Pharma Ltd.

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
January 05, 2026 08:00 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December ...
January 05, 2026 08:00 ET | Source: Genelux Corporation

Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials

-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials;...
January 05, 2026 08:00 ET | Source: Protara Therapeutics

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
January 05, 2026 08:00 ET | Source: Electra Therapeutics

Electra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and...